![logo](/logos/CLCS.webp)
Cell Source, Inc.
OTC:CLCS
0.5 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Cell Source, Inc. |
Symbool | CLCS |
Munteenheid | USD |
Prijs | 0.498 |
Beurswaarde | 19,002,311 |
Dividendpercentage | 0% |
52-weken bereik | 0 - 1.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Itamar Shimrat |
Website | https://www.cell-source.com |
An error occurred while fetching data.
Over Cell Source, Inc.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)